Brigatinib
ETOP 21-21
Phase 2 small_molecule terminated
Quick answer
Brigatinib for NSCLC, Stage III is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- NSCLC, Stage III
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated